T1	Participants 52 79	superficial bladder cancer.
T2	Participants 323 420	patients with primary or recurrent superficial bladder tumors, including carcinoma in situ (CIS).
T3	Participants 772 923	Reported are the incidence of side effects in 165 patients and the recurrence rate of tumors in 308 patients after a follow-up period of twelve months.